NCT03077165

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

A 10-week Randomized, Double-blind, Placebo-controlled, Prospective, International, Multicentre, Phase IIa Study of S42909 on Leg Ulcer Healing.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Ilkos Therapeutic Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.

Detailed description

S42909 is an inhibitor of β-Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase which also inhibits vascular leukocyte adhesion to endothelial cells, Matrix Metalloproteinase-2 (MMP-2) and Plasminogen Activator Inhibitor-1 (PAI-1) activity. It is proposed for development in the treatment of venous and mixed leg ulcers. This proof of concept study is a randomized, double-blind, placebo-controlled, multicenter, Phase IIa trial to evaluate the dose response of S42909 for the treatment of venous leg ulcers. Patients suffering from chronic venous disease and having at least one active venous leg ulcer will be selected at the selection visit (ASSE). One Reference Ulcer (RU) defined as the largest ulcer in size that is fitting the area selection criteria will be established. At ASSE, a first picture will be taken before cleansing and debridement and a second picture will be taken after cleansing and debridement. The investigator will check that the selection RU area is compliant with the selection criteria. Patients will start the selection period and will be switched from their current pharmacological and/or local treatment (if any) for venous leg ulcer to local wound care with sterile saline solution or sterile water, "non-active" dressings and standardized compression (same strength and type of compression). They will be administrated the placebo selection treatment for a period of fourteen days. Three (or four) working days before the inclusion visit, the participants will come to the site for a RU picture in order to get the RU area central measurement for inclusion visit (W000). At W000, the investigator will check that the inclusion RU area is compliant with the inclusion criteria. The investigator will also check that the participant is compliant with the selection treatment and stockings wearing. All participants found to be eligible for inclusion will be randomized to one of the following six groups - S42909: 100, 200, 400, 800 or 1200 mg per day- or placebo. The participants will enter a 6 weeks ambulatory Investigational Medicinal Product (IMP) treatment period on top of standard of care (standardized compression and local wound care with sterile saline solution or sterile water and "non-active" dressing) followed by a 2 weeks follow-up period of standard of care only. During this period the participants will return to the investigator's site for intermediate visits after one week (W001), two weeks (W002), three weeks (W003), four weeks (W004), six weeks (W006) and eight weeks (W008). Participants will continue receiving standardized compression therapy and local wound care (sterile saline solution or sterile water and "non-active" dressing) until the end of the study (W008).

Conditions

• Venous Leg Ulcer

Interventions

Type	Name	Description
DRUG	S42909 100 mg	50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
DRUG	S42909 200 mg	50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
DRUG	S42909 400 mg	200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
DRUG	S42909 800 mg	200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
DRUG	S42909 1200 mg	200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
DRUG	Placebo Oral Tablet	Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.

Timeline

• Start date: 2017-09-12
• Primary completion: 2019-12-12
• Completion: 2020-01-22
• First posted: 2017-03-10
• Last updated: 2020-10-08
• Results posted: 2020-10-08

Locations

80 sites across 11 countries: United States, Argentina, Austria, Brazil, Canada, Czechia, Hungary, Italy, Poland, Slovakia, Spain

Regulatory

• FDA-regulated drug study